Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/32903904/ below:

Non-Invasive Colorectal Cancer Screening: An Overview

Review

Affiliations

• ¹ John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham, United Kingdom.

• PMID: 32903904
• PMCID: PMC7445682
• DOI: 10.1159/000507701

Item in Clipboard

Review

Melanie Tepus et al. Gastrointest Tumors. 2020 Jul.

• ¹ John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham, United Kingdom.

• PMID: 32903904
• PMCID: PMC7445682
• DOI: 10.1159/000507701

Item in Clipboard

Background: Colorectal cancer (CRC) follows a protracted stepwise progression, from benign adenomas to malignant adenocarcinomas. If detected early, 90% of deaths are preventable. However, CRC is asymptomatic in its early-stage and arises sporadically within the population. Therefore, CRC screening is a public health priority.

Summary: Faecal immunochemical test (FIT) is gradually replacing guaiac faecal occult blood test and is now the most commonly used screening tool for CRC screening program globally. However, FIT is still limited by the haemoglobin degradation and the intermittent bleeding patterns, so that one in four CRC cases are still diagnosed in a late stage, leading to poor prognosis. A multi-target stool DNA test (Cologuard, a combination of NDRG4 and BMP3 DNA methylation, KRAS mutations, and haemoglobin) and a plasma SEPT9 DNA methylation test (Epi proColon) are non-invasive tools also approved by the US FDA, but those screening approaches are not cost-effective, and the detection accuracies remain unsatisfactory. In addition to the approved tests, faecal-/blood-based microRNA and CRC-related gut microbiome screening markers are under development, with work ongoing to find the best combination of molecular biomarkers which maximise the screening sensitivity and specificity.

Key message: Maximising the detection accuracy with a cost-effective approach for non-invasive CRC screening is urgently needed to further reduce the incidence of CRC and associated mortality rates.

Keywords: Colorectal cancer screening; Diagnostic biomarkers; Gut microbiota; Tumour biomarkers; microRNA.

Copyright © 2020 by S. Karger AG, Basel.

PubMed Disclaimer

The authors have no conflicts of interest to declare.

• Biomarkers for detecting colorectal cancer non-invasively: DNA, RNA or proteins?

  Loktionov A. Loktionov A. World J Gastrointest Oncol. 2020 Feb 15;12(2):124-148. doi: 10.4251/wjgo.v12.i2.124. World J Gastrointest Oncol. 2020. PMID: 32104546 Free PMC article. Review.

• Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.

  Medical Advisory Secretariat. Medical Advisory Secretariat. Ont Health Technol Assess Ser. 2009;9(10):1-40. Epub 2009 Sep 1. Ont Health Technol Assess Ser. 2009. PMID: 23074514 Free PMC article.

• Stool DNA methylation assays in colorectal cancer screening.

  Kadiyska T, Nossikoff A. Kadiyska T, et al. World J Gastroenterol. 2015 Sep 21;21(35):10057-61. doi: 10.3748/wjg.v21.i35.10057. World J Gastroenterol. 2015. PMID: 26401070 Free PMC article. Review.

• Clinical and Budget Impact of Increasing Colorectal Cancer Screening by Blood- and Stool-Based Testing.

  Roth JA, deVos T, Ramsey SD. Roth JA, et al. Am Health Drug Benefits. 2019 Sep;12(5):256-262. Am Health Drug Benefits. 2019. PMID: 32015794 Free PMC article.

• Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know.

  Tinmouth J, Lansdorp-Vogelaar I, Allison JE. Tinmouth J, et al. Gut. 2015 Aug;64(8):1327-37. doi: 10.1136/gutjnl-2014-308074. Epub 2015 Jun 3. Gut. 2015. PMID: 26041750 Review.

• Fecal Multidimensional Assay for Non-Invasive Detection of Colorectal Cancer: Fecal Immunochemical Test, Stool DNA Mutation, Methylation, and Intestinal Bacteria Analysis.

  Mo S, Wang H, Han L, Xiang W, Dai W, Zhao P, Pei F, Su Z, Ma C, Li Q, Wang Z, Cai S, Wang H, Liu R, Cai G. Mo S, et al. Front Oncol. 2021 Feb 25;11:643136. doi: 10.3389/fonc.2021.643136. eCollection 2021. Front Oncol. 2021. PMID: 33718241 Free PMC article.

• Developing an m5C regulator-mediated RNA methylation modification signature to predict prognosis and immunotherapy efficacy in rectal cancer.

  Zhang R, Gan W, Zong J, Hou Y, Zhou M, Yan Z, Li T, Lv S, Zeng Z, Wang W, Zhang F, Yang M. Zhang R, et al. Front Immunol. 2023 Feb 22;14:1054700. doi: 10.3389/fimmu.2023.1054700. eCollection 2023. Front Immunol. 2023. PMID: 36911744 Free PMC article.

• Combined SEPT9 and BMP3 methylation in plasma for colorectal cancer early detection and screening in a Brazilian population.

  Lima AB, Dos Reis MB, Matsushita M, Dos Reis MT, de Oliveira MA, Reis RM, Guimarães DP. Lima AB, et al. Cancer Med. 2023 Aug;12(15):15854-15867. doi: 10.1002/cam4.6224. Epub 2023 Jun 20. Cancer Med. 2023. PMID: 37338022 Free PMC article.

• Joint Asian Pacific Association of Gastroenterology (APAGE)-Asian Pacific Society of Digestive Endoscopy (APSDE) clinical practice guidelines on the use of non-invasive biomarkers for diagnosis of colorectal neoplasia.

  Chan FKL, Wong MCS, Chan AT, East JE, Chiu HM, Makharia GK, Weller D, Ooi CJ, Limsrivilai J, Saito Y, Hang DV, Emery JD, Makmun D, Wu K, Ali RAR, Ng SC. Chan FKL, et al. Gut. 2023 Jul;72(7):1240-1254. doi: 10.1136/gutjnl-2023-329429. Epub 2023 Apr 5. Gut. 2023. PMID: 37019620 Free PMC article.

• The Role of microRNAs in Development of Colitis-Associated Colorectal Cancer.

  Bocchetti M, Ferraro MG, Ricciardiello F, Ottaiano A, Luce A, Cossu AM, Scrima M, Leung WY, Abate M, Stiuso P, Caraglia M, Zappavigna S, Yau TO. Bocchetti M, et al. Int J Mol Sci. 2021 Apr 12;22(8):3967. doi: 10.3390/ijms22083967. Int J Mol Sci. 2021. PMID: 33921348 Free PMC article. Review.

1. 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68((6)):394–424. - PubMed
2. 1. Yau TO. Precision treatment in colorectal cancer: now and the future. JGH Open. 2019 Feb;3((5)):361–9. - PMC - PubMed
3. 1. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017 Apr;66((4)):683–91. - PubMed
4. 1. Schreuders EH, Ruco A, Rabeneck L, Schoen RE, Sung JJ, Young GP, et al. Colorectal cancer screening: a global overview of existing programmes. Gut. 2015 Oct;64((10)):1637–49. - PubMed
5. 1. Simon K. Colorectal cancer development and advances in screening. Clin Interv Aging. 2016 Jul;11:967–76. - PMC - PubMed

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3